Loading
Prostate Cancer Treatment and Research / Epigenetics and DNA Methylation / Sexual Differentiation and Disorders · Journal article
Proceedings of the National Academy of Sciences · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic cell line study proposing that minimal-length (≤17) CAG repeats in the androgen receptor gene create a hyperactive AR–LSD1 chromatin axis that drives metabolic reprogramming and may explain prostate cancer disparities in men of African ancestry. The work identifies a plausible biological pathway but lacks in vivo validation, patient outcome data, or functional evidence that this mechanism actually drives clinical disease or therapy resistance in humans.
Cell line model study with mechanistic investigation. Isogenic prostate cancer cell lines modified to express AR variants; no patient enrollment or clinical cohort.. Intervention: Isogenic AR with minimal-length CAG repeats (≤17); LSD1 inhibition.. Compared with: Isogenic AR with normal-length CAG repeats (implied); untreated cells or vehicle control (implied by LSD1 inhibition experiment)..
Minimal-length CAG repeats (≤17) are found in over 10% of men of African ancestry and may contribute to increased prostate cancer risk and worse outcomes in this population. Isogenic prostate cancer cell lines with ultrashort polyQ AR exhibit attenuated response to AR-targeted therapies, markedly enhanced protein stability, and expanded chromatin binding. Ultrashort polyQ AR upregulates metabolic gene networks leading to enhanced glycolysis and reduced mitochondrial respiration.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated in patient cohorts and in vivo models, this work could inform understanding of AR polymorphism-driven prostate cancer disparities and suggest LSD1 inhibition as a therapeutic strategy for this genotype. Currently, this remains a mechanistic hypothesis requiring substantial further evidence before clinical application.
Cell line study identifying a mechanistic link between AR CAG repeat polymorphism and metabolic reprogramming; lacks in vivo validation, patient outcome data, or clinical endpoint evidence.
As stated by the source record.
Quoted from the source exactly as published.
If validated in patient cohorts and in vivo models, this work could inform understanding of AR polymorphism-driven prostate cancer disparities and suggest LSD1 inhibition as a therapeutic strategy for this genotype. Currently, this remains a mechanistic hypothesis requiring substantial further evidence before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The polymorphic CAG trinucleotide repeat in the androgen receptor ( AR ) gene encodes a variable-length N-terminal polyglutamine (polyQ) tract that modulates AR transcriptional activity, with shorter tracts generally enhancing AR activity. While the majority of men harbor CAG repeats longer than 17, a small subset carry minimal-length CAG repeats (≤17) in AR. These alleles are primarily found in men of African ancestry, accounting for over 10% of the population, and may significantly contribute to the increased prostate cancer (PCa) risk and worse clinical outcomes observed in this population. However, how this distinct pattern of polymorphism influences AR–chromatin interaction, metabolic reprogramming, and therapeutic response remains unclear. Here, we established isogenic PCa cell lines harboring AR with a minimal length of CAG repeats that encode an ultrashort polyQ tract and found that this AR variant exhibits attenuated response to AR-targeted therapies with markedly enhanced protein stability, expanded chromatin binding, and a reprogrammed transcriptional profile. The ultrashort polyQ AR also reshapes global FOXA1 occupancy and upregulates metabolic gene networks, leading to enhanced glycolysis and reduced mitochondria respiration. Mechanistically, we identify a strengthened AR–LSD1 interaction and show that LSD1 inhibition suppresses the expanded AR chromatin binding, impairs the glycolytic reprogramming, and reduces tumor growth. Together, these findings define a hyperactive AR–LSD1 chromatin axis driven by minimal-length CAG repeats in AR and reveal a mechanistic link between inherited AR polymorphism, AR-mediated epigenetic-metabolic remodeling, and population-associated disparities in prostate cancer biology.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.